Improved Therapeutic Efficacy of MT102, a New Anti-Inflammatory Agent, Via a Self-Microemulsifying Drug Delivery System, in Ulcerative Colitis Mice

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Dec 23

PMID 38140061

Authors

Kshitis Chandra Baral

Sang Hoon Lee

Jae Geun Song

Seong Hoon Jeong

Hyo-Kyung Han

Affiliations

Soon will be listed here.

Abstract

MT-102 is a new anti-inflammatory agent derived from and . Its therapeutic potential is hindered by low aqueous solubility, impacting its in vivo efficacy. Therefore, this study aimed to develop a self-microemulsifying drug delivery system (SMEDDS) for MT-102 to enhance its oral efficacy in treating ulcerative colitis. Solubility assessment in different oils, surfactants, and cosurfactants led to a SMEDDS formulation of MT-102 using Capmul MCM, Tween 80, and propylene glycol. Based on a pseudoternary phase diagram, the optimal SMEDDS composition was selected, which consisted of 15% Capmul MCM, 42.5% Tween 80, and 42.5% propylene glycol. The resulting optimized SMEDDS (SMEDDS-F1) exhibited a narrow size distribution (177.5 ± 2.80 nm) and high indirubin content (275 ± 5.58 µg/g, a biomarker). Across an acidic to neutral pH range, SMEDDS-F1 showed rapid and extensive indirubin release, with dissolution rates approximately 15-fold higher than pure MT-102. Furthermore, oral administration of SMEDDS-F1 effectively mitigated inflammatory progression and symptoms in a mouse model of ulcerative colitis, whereas pure MT-102 was ineffective. SMEDDS-F1 minimized body weight loss (less than 5%) without any significant change in colon length and the morphology of colonic tissues, compared to those of the healthy control group. In addition, oral administration of SMEDDS-F1 significantly inhibited the secretion of pro-inflammatory cytokines such as IL-6 and TNF-α. In conclusion, the SMEDDS-F1 formulation employing Capmul MCM, Tween 80, and propylene glycol (15:42.5:42.5, /) enhances the solubility and therapeutic efficacy of MT-102.

References

Sunazuka Y, Ueda K, Higashi K, Tanaka Y, Moribe K . Combined effects of the drug distribution and mucus diffusion properties of self-microemulsifying drug delivery systems on the oral absorption of fenofibrate. Int J Pharm. 2018; 546(1-2):263-271. DOI: 10.1016/j.ijpharm.2018.05.031. View

Bajracharya R, Song J, Lee S, Jeong S, Han H . Enhanced Oral Bioavailability of MT-102, a New Anti-inflammatory Agent, via a Ternary Solid Dispersion Formulation. Pharmaceutics. 2022; 14(7). PMC: 9323944. DOI: 10.3390/pharmaceutics14071510. View

Bhalani D, Nutan B, Kumar A, Chandel A . Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines. 2022; 10(9). PMC: 9495787. DOI: 10.3390/biomedicines10092055. View

Mohsin K . Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion. AAPS PharmSciTech. 2012; 13(2):637-46. PMC: 3364387. DOI: 10.1208/s12249-012-9787-2. View

Parveen R, Baboota S, Ali J, Ahuja A, Vasudev S, Ahmad S . Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies. Int J Pharm. 2011; 413(1-2):245-53. DOI: 10.1016/j.ijpharm.2011.04.041. View

Rahman M, Hussain A, Sarfaraj Hussain M, Aamir Mirza M, Iqbal Z . Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS). Drug Dev Ind Pharm. 2012; 39(1):1-19. DOI: 10.3109/03639045.2012.660949. View

Hossain S, Joyce P, Parrow A, Joemetsa S, Hook F, Larsson P . Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers. Mol Pharm. 2020; 17(11):4226-4240. PMC: 7610231. DOI: 10.1021/acs.molpharmaceut.0c00668. View

Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A . Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2017; 11(1):1-10. DOI: 10.1007/s12328-017-0813-5. View

Bou-Chacra N, Melo K, Morales I, Stippler E, Kesisoglou F, Yazdanian M . Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System. AAPS J. 2017; 19(4):989-1001. DOI: 10.1208/s12248-017-0085-5. View

10.

Gao W, Guo Y, Wang C, Lin Y, Yu L, Sheng T . Indirubin ameliorates dextran sulfate sodium-induced ulcerative colitis in mice through the inhibition of inflammation and the induction of Foxp3-expressing regulatory T cells. Acta Histochem. 2016; 118(6):606-614. DOI: 10.1016/j.acthis.2016.06.004. View

11.

Jantratid E, Janssen N, Reppas C, Dressman J . Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 2008; 25(7):1663-76. DOI: 10.1007/s11095-008-9569-4. View

12.

Kim C, Kovacs-Nolan J, Yang C, Archbold T, Fan M, Mine Y . L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim Biophys Acta. 2009; 1790(10):1161-9. DOI: 10.1016/j.bbagen.2009.05.018. View

13.

Dokania S, Joshi A . Self-microemulsifying drug delivery system (SMEDDS)--challenges and road ahead. Drug Deliv. 2014; 22(6):675-90. DOI: 10.3109/10717544.2014.896058. View

14.

Liu C, Chen L, Hu Y, Dai J, Ma B, Tang Q . Self-Microemulsifying Drug Delivery System for Improved Oral Delivery and Hypnotic Efficacy of Ferulic Acid. Int J Nanomedicine. 2020; 15:2059-2070. PMC: 7104137. DOI: 10.2147/IJN.S240449. View

15.

Baral K, Song J, Lee S, Bajracharya R, Sreenivasulu G, Kim M . Enhanced Bioavailability of AC1497, a Novel Anticancer Drug Candidate, via a Self-Nanoemulsifying Drug Delivery System. Pharmaceutics. 2021; 13(8). PMC: 8398171. DOI: 10.3390/pharmaceutics13081142. View

16.

Riansuwan W, Limsrivilai J . Current status of IBD and surgery of Crohn's disease in Thailand. Ann Gastroenterol Surg. 2021; 5(5):597-603. PMC: 8452468. DOI: 10.1002/ags3.12470. View

17.

Li C, Wang J, Ma R, Li L, Wu W, Cai D . Natural-derived alkaloids exhibit great potential in the treatment of ulcerative colitis. Pharmacol Res. 2021; 175:105972. DOI: 10.1016/j.phrs.2021.105972. View

18.

Zhang K, Wang Q, Yang Q, Wei Q, Man N, Adu-Frimpong M . Enhancement of Oral Bioavailability and Anti-hyperuricemic Activity of Isoliquiritigenin via Self-Microemulsifying Drug Delivery System. AAPS PharmSciTech. 2019; 20(5):218. DOI: 10.1208/s12249-019-1421-0. View

19.

Xie J, Tian S, Liu J, Huang S, Yang M, Yang X . Combination Therapy with Indigo and Indirubin for Ulcerative Colitis via Reinforcing Intestinal Barrier Function. Oxid Med Cell Longev. 2023; 2023:2894695. PMC: 9943625. DOI: 10.1155/2023/2894695. View

20.

Tokuyasu N, Shomori K, Amano K, Honjo S, Sakamoto T, Watanabe J . Indirubin, a Constituent of the Chinese Herbal Medicine Qing-Dai, Attenuates Dextran Sulfate Sodium-induced Murine Colitis. Yonago Acta Med. 2018; 61(2):128-136. PMC: 6015798. View